Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Raab on the Rationale for Adding Teclistamab to Daratumumab-Based Induction in NDMM

November 12th 2025

Marc S. Raab, MD, discusses the rationale for assessing teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma

November 11th 2025

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 11/2

November 8th 2025

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

November 7th 2025

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

Dr Jakubowiak on the ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma

November 6th 2025

Andrzej Jakubowiak, MD, PhD, discusses the rationale of the phase 3 ATLAS study in patients with multiple myeloma.

FDA Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma

November 6th 2025

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

November 6th 2025

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R Myeloma

November 4th 2025

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

October 31st 2025

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Dr Mouhieddine on Future Directions With Ferritin and ALC as Biomarkers in Myeloma

October 28th 2025

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.

The OncFive: Top Oncology Articles for the Week of 10/19

October 25th 2025

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

FDA Approves Belantamab Mafodotin Plus Bortezomib and Dexamethasone for R/R Multiple Myeloma

October 23rd 2025

Arlo-Cel Delivers High, Durable Responses With Manageable Safety in R/R Myeloma

October 22nd 2025

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

Dr Mouhieddine on Clinical Implications of Ferritin and ALC as Biomarkers in Myeloma

October 21st 2025

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

Teclistamab Plus Daratumumab Boosts Survival in R/R Myeloma

October 16th 2025

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Dr Mouhieddine on Ferritin and ALC As Markers of Bispecific Antibody Response in Myeloma

October 14th 2025

Tarek Mouhieddine, MD, discusses the use of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory multiple myeloma.

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma

October 14th 2025

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma

October 13th 2025

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.